Clinical Scorecard: Federal Data Indicates a Decline in U.S. Overdose Deaths Throughout Much of 2025
At a Glance
Category
Detail
Condition
Drug overdose epidemic involving opioids and illicit fentanyl
Key Mechanisms
Decline in overdose deaths linked to reduced fentanyl potency, increased naloxone availability, expanded addiction treatment, and changes in drug use patterns
Target Population
U.S. population affected by opioid and illicit drug use
Care Setting
Public health and addiction treatment settings across the United States
Key Highlights
U.S. overdose deaths fell for over two years, with a 27% decline in 2024, the largest one-year drop recorded.
Declines occurred in 45 states, with exceptions including Arizona, Hawaii, Kansas, New Mexico, and North Dakota.
Potential contributing factors include regulatory changes in China reducing fentanyl precursors, expanded naloxone access, addiction treatment, and the end of pandemic stimulus payments.
Guideline-Based Recommendations
Diagnosis
Monitor overdose trends using federal and state data to identify emerging patterns.
Management
Increase availability and use of naloxone to reverse overdoses.
Expand access to addiction treatment services.
Consider socio-economic factors influencing drug use and overdose risk.
Monitoring & Follow-up
Track monthly provisional overdose death data to assess epidemic trends.
Monitor drug supply changes, including fentanyl potency and availability.
Evaluate impact of policy changes on overdose rates.
Risks
Potential resurgence of overdose deaths if fentanyl precursor regulation weakens.
Economic stimulus payments may influence drug purchasing and overdose risk.
Incomplete reporting of overdose deaths may affect data accuracy.
Patient & Prescribing Data
Individuals at risk of opioid and illicit drug overdose in the U.S.
Increased naloxone distribution and addiction treatment expansion correlate with overdose death declines; socioeconomic interventions may also impact outcomes.
Clinical Best Practices
Utilize naloxone widely for overdose reversal in community and clinical settings.
Provide comprehensive addiction treatment and support services.
Incorporate surveillance data to guide public health interventions.
Address social determinants of health that contribute to drug use and overdose risk.
